Michael Davis becomes Cyanotech chairman
Hawaiian microalgae technology company looks forward to continuing support of its major shareholder
Davis was vice-chairman of the board and has been a director of Cyanotech since March 2003.
‘Michael has been a key influence in helping Cyanotech sharpen its business model and market focus in recent years,’ said Brent Bailey, president and ceo. ‘We look forward to his continuing support and leadership as chairman of the board.’
Cyanotech Corporation, a microalgae technology specialist, produces BioAstin Natural Astaxanthin and Hawaiian Spirulina Pacifica, which are natural, functional nutrients.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing
As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Ingredients
The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)
Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients
Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo
Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Ingredients
Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply
The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity